Literature DB >> 9010622

Human UGT2B7 catalyzes morphine glucuronidation.

B L Coffman1, G R Rios, C D King, T R Tephly.   

Abstract

A human UDP-glucuronosyltransferase (UGT) catalyzing the glucuronidation of morphine has been identified. A full length cDNA was isolated from a human liver cDNA library and found to be identical to the UGT2B7 form having a tyrosine at position 288. This cDNA was transfected into HK 293 cells, and stable expression was achieved. Cell homogenates and membrane preparations from HK 293 cells expressing UGT2B7 catalyzed the glucuronidation of morphine and other clinically significant opioid agonists, antagonists, and partial agonists. UGT2B7 catalyzed morphine glucuronidation at the 3- and 6-hydroxy positions and also mediated the formation of codeine-6-glucuronide from codeine. This represents the first demonstration of a UGT capable of catalyzing the glucuronidation of both the 3- and 6-positions of opioids. Since humans excrete morphine-3-glucuronide and morphine-6-glucuronide after morphine administration, it is likely that UGT2B7 is a major isoform in humans responsible for the metabolism of this important drug and its surrogates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010622

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  72 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 2.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

3.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

4.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

5.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

Review 6.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

7.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

Authors:  L Iyer; C D King; P F Whitington; M D Green; S K Roy; T R Tephly; B L Coffman; M J Ratain
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

8.  Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma.

Authors:  Fei Tang; Henrietta Bada; Chee M Ng; Markos Leggas
Journal:  Biomed Chromatogr       Date:  2019-03-20       Impact factor: 1.902

Review 9.  A perspective on efflux transport proteins in the liver.

Authors:  K Köck; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

10.  Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.

Authors:  Hong-Jaan Wang; Cheng-Huei Hsiong; Shung-Tai Ho; Min-Jen Lin; Tung-Yuan Shih; Pei-Wei Huang; Oliver Yoa-Pu Hu
Journal:  Pharm Res       Date:  2014-02-14       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.